Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease
Objective: In this study, we aimed to investigate whether hypoxic conditions can activate cerebral astrocytes and explore their protective effects on α-synuclein pre-formed fibril (PFF)-treated…Improving inpatient medication management in hospitalized Parkinson’s patients
Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial
Objective: To evaluating the effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial Background:…Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort
Objective: To examine change in clinical characteristics in LRRK2 G2019S carriers with Parkinson’s disease (PD) and without PD (non-manifest carriers) enrolled in Virtual Assessment of…Longitudinal brain volume decline in PD with RBD and olfactory dysfunction
Objective: To elucidate longitudinal brain atrophies in PD with or without RBD and anosmia at baseline. Background: REM sleep behavior disorder (RBD) and olfactory dysfunction…Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson’s Disease and Movement Disorders Clinic
Objective: To evaluate the impact of pharmacist participation in Parkinson’s disease and movement disorders clinic on the number of drug-related problems (DRPs), clinical outcomes, and…monogenic parkinson´s disease in a chilean cohort
Objective: To describe the minimum prevalence and distribution of monogenic forms of PD in a chilean cohort Background: About 3–5% of Parkinson’s disease (PD) patients…Analysis of subthalamic-nuclei deep brain stimulation using radiomic feature-manifestations: a quantitative approach
Objective: To estimate STN by IPGs induced with DBS effects for Parkinson's by ‘radiomic-features(RF)’/symptoms-manifestations attained as of pre-opMRI, study possibility of ‘RF’ of amygdala-nucleus’ plus…
- « Previous Page
- 1
- …
- 244
- 245
- 246
- 247
- 248
- …
- 436
- Next Page »